Fulcrum Therapeutics' shares plummeted over 50% after the company announced it would discontinue the development of its lead sickle-cell disease drug, pociredir, following safety concerns raised by the U.S. Food and Drug Administration (FDA). The decision comes amidst a challenging landscape for sickle-cell drug development, with Pfizer having withdrawn its therapy Oxbryta in 2024 due to similar concerns.
Pociredir was designed to increase fetal hemoglobin levels by targeting a sub-unit in the PRC2 protein complex, which typically suppresses its production. However, the FDA expressed concerns over malignancy risks associated with drugs targeting this protein complex, following the global withdrawal of Ipsen's cancer drug, Tazverik, earlier this year. Fulcrum argued that pociredir targets a different component of the PRC2 complex, but the FDA maintained that all drugs acting on the complex pose similar risks.
Truist analyst Gregory Renza noted that the FDA did not differentiate between sub-units of the PRC2, viewing the entire complex as carrying a systemic cancer risk. Despite the strong efficacy data and unmet need in the market, at least three brokerages downgraded Fulcrum's stock and lowered their price targets.
“We're a bit surprised by the discontinuation in light of strong efficacy data and unmet need.”
James Condulis, Stifel Analyst
The company is now considering strategic alternatives, including a potential sale or merger, and has initiated cost-cutting measures to preserve cash. Fulcrum stated that no new safety concerns had emerged in clinical trials and that pociredir had shown increases in fetal hemoglobin, potentially reducing disease severity in sickle-cell patients.
The setback highlights the ongoing challenges in developing effective treatments for sickle-cell disease, an inherited blood disorder that can cause pain, anemia, and organ damage, significantly reducing life expectancy. The withdrawal of therapies like Oxbryta and Tazverik underscores the regulatory hurdles and safety concerns that continue to impact drug development in this area.
“The regulator did not differentiate between sub-units of the PRC2, instead viewing the entire complex as carrying a systemic cancer risk.”
Gregory Renza, Truist Analyst
Background
The setback highlights the ongoing challenges in developing effective treatments for sickle-cell disease, an inherited blood disorder that can cause pain, anemia, and organ damage, significantly reducing life expectancy. The withdrawal of therapies like Oxbryta and Tazverik underscores the regulatory hurdles and safety concerns that continue to impact drug development in this area.
Looking forward, Fulcrum's strategic review and potential restructuring could reshape its future, while the broader market keeps an eye on regulatory developments and emerging therapies in the sickle-cell treatment landscape.
